import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "hexarelin-cd36-cardiac-mechanism-jun2026",
  title: "Hexarelin: CD36-Mediated Cardioprotection and GH Secretagogue Research",
  description:
    "Hexarelin is a synthetic hexapeptide studied for potent GH-releasing effects and a GH-independent cardioprotective mechanism via CD36 receptor binding. This overview covers the published preclinical and mechanistic data.",
  category: "Compound Profiles",
  readMinutes: 9,
  publishedAt: "2026-06-16",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Hexarelin (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂) is a synthetic hexapeptide and potent growth hormone secretagogue (GHS) developed in the early 1990s. It acts as an agonist at the GHS-R1a receptor — the ghrelin receptor — and has been studied for GH-releasing effects, hypothalamic-pituitary axis interactions, and a notable cardioprotective profile that appears independent of GH secretion.",
    },
    {
      type: "heading",
      text: "Mechanism of Action",
    },
    {
      type: "subheading",
      text: "GHS-R1a Agonism",
    },
    {
      type: "paragraph",
      text: "Like other GHS compounds (Ipamorelin, GHRP-6, MK-677), Hexarelin binds to and activates GHS-R1a expressed in the pituitary, hypothalamus, and peripheral tissues. GHS-R1a activation in the pituitary triggers GH release; in peripheral tissues it mediates several non-GH effects. Hexarelin is among the most potent GHS compounds studied, producing substantial GH release at relatively low concentrations in preclinical models. However, unlike some GHSs, Hexarelin shows significant desensitization with continuous administration — a relevant consideration for research protocol design.",
    },
    {
      type: "subheading",
      text: "CD36 Receptor Binding",
    },
    {
      type: "paragraph",
      text: "A critical and distinguishing feature of Hexarelin research is its interaction with CD36 — a scavenger receptor expressed on cardiac myocytes, endothelial cells, and macrophages. CD36 has multiple roles including fatty acid uptake and utilization in cardiac tissue, oxidized LDL recognition relevant to atherosclerosis, and angiogenesis regulation. Hexarelin's binding to CD36 in cardiac tissue is thought to mediate cardioprotective effects independently of GH or IGF-1 elevation, established in GH-deficient animal models where cardioprotective effects persisted despite negligible GH response.",
    },
    {
      type: "heading",
      text: "Growth Hormone Research Data",
    },
    {
      type: "paragraph",
      text: "In comparative studies examining GH-releasing potency, Hexarelin produces greater peak GH secretion than GHRP-6 and Ipamorelin in most rodent models. This potency advantage is partially offset by rapid desensitization — repeated Hexarelin administration leads to blunted GH response more rapidly than Ipamorelin. Co-administration with GHRH analogs produces synergistic GH release, consistent with other GHSs.",
    },
    {
      type: "callout",
      text: "Unlike Ipamorelin, Hexarelin is not selective for GH at higher doses — it stimulates cortisol and prolactin secretion in a dose-dependent manner. This is an important consideration for protocols where hormonal specificity is required.",
    },
    {
      type: "heading",
      text: "Cardioprotective Research",
    },
    {
      type: "subheading",
      text: "Ischemia-Reperfusion Injury",
    },
    {
      type: "paragraph",
      text: "Studies in isolated heart preparations and in vivo rodent models have documented that Hexarelin reduces ischemia-reperfusion (I/R) injury — the cell death and dysfunction occurring when blood flow is restored after ischemia. Locatelli et al. (1999) and subsequent work demonstrated that Hexarelin pre-treatment in rats reduced infarct size following coronary occlusion and reperfusion. Critically, these effects were present in hypophysectomized (GH-deficient) animals, confirming the mechanism is not GH-dependent, and blocked by CD36 antagonism, confirming CD36 as the relevant mediator.",
    },
    {
      type: "subheading",
      text: "Cardiac Function in GH Deficiency",
    },
    {
      type: "paragraph",
      text: "GH-deficient patients and animal models consistently show impaired cardiac function — reduced cardiac output, increased vascular resistance, and altered cardiac morphology. Hexarelin treatment in GH-deficient models has shown improved cardiac output and ejection fraction, reduction in left ventricular hypertrophy in some models, and improved ventricular contractility in isolated heart preparations. Some of these effects are mediated via GH/IGF-1, while others — particularly contractility effects — appear to involve direct cardiac receptor activation.",
    },
    {
      type: "subheading",
      text: "Anti-Apoptotic Effects",
    },
    {
      type: "list",
      items: [
        "Reduced cardiomyocyte apoptosis following ischemic stress",
        "Upregulation of anti-apoptotic proteins (Bcl-2 family)",
        "Reduced cytochrome c release from mitochondria",
      ],
    },
    {
      type: "heading",
      text: "The CD36 Pathway as a Research Focus",
    },
    {
      type: "paragraph",
      text: "The identification of CD36 as a Hexarelin receptor in cardiac tissue opened a new dimension of GHS research. CD36 had been primarily studied in lipid metabolism and atherosclerosis, but Hexarelin research has implicated it in cardioprotection signaling, anti-inflammatory effects in vascular tissue, and potential relevance to metabolic syndrome research — since CD36 is involved in fatty acid uptake dysregulation in obesity. This makes Hexarelin not only a GHS research tool but also a pharmacological probe for CD36 function with independent scientific value.",
    },
    {
      type: "heading",
      text: "Research Protocol Considerations",
    },
    {
      type: "table",
      headers: ["Parameter", "Notes"],
      rows: [
        ["Solubility", "Water-soluble; reconstitute in bacteriostatic water"],
        ["Stability in solution", "Store at 2–8°C; use within 4 weeks of reconstitution"],
        ["Desensitization", "Significant with continuous administration; intermittent protocols recommended"],
        ["GH selectivity", "Less selective than Ipamorelin; monitor cortisol and prolactin in GH-focused protocols"],
        ["Purity requirement", "HPLC ≥98%; mass spec identity confirmation essential"],
      ],
    },
    {
      type: "heading",
      text: "Summary",
    },
    {
      type: "paragraph",
      text: "Hexarelin occupies a unique position in GHS research: it is among the most potent GH-releasing peptides studied, while simultaneously demonstrating cardioprotective effects through a GH-independent CD36-mediated pathway. The ischemia-reperfusion protection data is well-replicated in animal models and the CD36 mechanism is mechanistically characterized. Its lower GH selectivity compared to Ipamorelin and its rapid desensitization profile are relevant practical considerations for protocol design.",
    },
    {
      type: "disclaimer",
      text: "For research purposes only. Not intended for human use.",
    },
  ],
};
